BR112022023101A2 - Composição compreendendo uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv para uso no tratamento ou prevenção de infecção por hcv, uso de uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv, e método de tratamento ou prevenção de infecção por hcv - Google Patents

Composição compreendendo uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv para uso no tratamento ou prevenção de infecção por hcv, uso de uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv, e método de tratamento ou prevenção de infecção por hcv

Info

Publication number
BR112022023101A2
BR112022023101A2 BR112022023101A BR112022023101A BR112022023101A2 BR 112022023101 A2 BR112022023101 A2 BR 112022023101A2 BR 112022023101 A BR112022023101 A BR 112022023101A BR 112022023101 A BR112022023101 A BR 112022023101A BR 112022023101 A2 BR112022023101 A2 BR 112022023101A2
Authority
BR
Brazil
Prior art keywords
hcv
nucleic acid
acid molecule
polypeptide
prevention
Prior art date
Application number
BR112022023101A
Other languages
English (en)
Portuguese (pt)
Inventor
Drummer Heidi
Jane Barnes Eleanor
Kumar Chinnakannan Senthil
Original Assignee
Macfarlane Burnet Institute For Medical Res And Public Health Limited
Chancellor Masters And Scholars Of The Univ Of Oxford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2020901506A external-priority patent/AU2020901506A0/en
Application filed by Macfarlane Burnet Institute For Medical Res And Public Health Limited, Chancellor Masters And Scholars Of The Univ Of Oxford filed Critical Macfarlane Burnet Institute For Medical Res And Public Health Limited
Publication of BR112022023101A2 publication Critical patent/BR112022023101A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C07K14/1816—Flaviviridae, e.g. pestivirus, mucosal disease virus, bovine viral diarrhoea virus, classical swine fever virus (hog cholera virus), border disease virus
    • C07K14/1833—Hepatitis C; Hepatitis NANB
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022023101A 2020-05-11 2021-05-11 Composição compreendendo uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv para uso no tratamento ou prevenção de infecção por hcv, uso de uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv, e método de tratamento ou prevenção de infecção por hcv BR112022023101A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2020901506A AU2020901506A0 (en) 2020-05-11 Compositions and their prophylactic or therapeutic use
PCT/AU2021/050437 WO2021226664A1 (en) 2020-05-11 2021-05-11 A hepatitis c nucleic acid vaccine comprising a variable domain deleted e2 polypeptide

Publications (1)

Publication Number Publication Date
BR112022023101A2 true BR112022023101A2 (pt) 2023-01-17

Family

ID=78525848

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023101A BR112022023101A2 (pt) 2020-05-11 2021-05-11 Composição compreendendo uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv para uso no tratamento ou prevenção de infecção por hcv, uso de uma molécula de ácido nucleico que codifica um polipeptídeo e2 excluído de domínio variável de hcv, e método de tratamento ou prevenção de infecção por hcv

Country Status (8)

Country Link
US (1) US20230181726A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149541A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526045A (cg-RX-API-DMAC7.html)
CN (1) CN115843270A (cg-RX-API-DMAC7.html)
AU (1) AU2021270053A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022023101A2 (cg-RX-API-DMAC7.html)
CA (1) CA3178547A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021226664A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12576041B1 (en) * 2021-07-14 2026-03-17 Dean Nakamura Transient expression of biologic materials

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021807A1 (en) * 1999-09-23 2001-03-29 The Government Of The United States Of America As Represented By The Secretary, Department Of Health Services Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
CA2610919C (en) * 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
EP2061805B1 (en) * 2006-08-25 2020-02-12 Macfarlane Burnet Institute for Medical Research and Public Health Limited Recombinant hcv e2 glycoprotein
CA2726914A1 (en) * 2008-06-03 2009-12-10 Okairos Ag A vaccine for the prevention and therapy of hcv infections
US9079950B2 (en) * 2010-08-04 2015-07-14 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd Modified Hepatitis C virus proteins
WO2016141201A2 (en) * 2015-03-04 2016-09-09 University Of Maryland Rational vaccine design for hepatitis c virus
CN110049993A (zh) * 2016-09-29 2019-07-23 麦克法兰布奈特医疗研究与公共健康研究所有限公司 组装的糖蛋白

Also Published As

Publication number Publication date
EP4149541A4 (en) 2024-06-05
AU2021270053A1 (en) 2022-12-15
JP2023526045A (ja) 2023-06-20
CA3178547A1 (en) 2021-11-18
EP4149541A1 (en) 2023-03-22
CN115843270A (zh) 2023-03-24
WO2021226664A1 (en) 2021-11-18
US20230181726A1 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP7827321B2 (ja) エピゲノム編集のための組成物および方法
Appelberg et al. Nucleoside-modified mRNA vaccines protect IFNAR–/–mice against Crimean-Congo hemorrhagic fever virus infection
ES2886480T3 (es) Métodos y composiciones para el tratamiento guiado por ARN de una infección por VIH
AU2017219605B2 (en) Excision of retroviral nucleic acid sequences
US12215345B2 (en) Compositions and methods for the induction and tuning of gene expression
BR112021024786A2 (pt) Construção de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método para preparar a construção de rna, vacina, método para modificar uma célula ex vivo ou in vitro e célula modificada
Kint et al. Infectious bronchitis coronavirus limits interferon production by inducing a host shutoff that requires accessory protein 5b
ES2747833T3 (es) Composiciones y procedimientos para la escisión in vivo del ADN proviral del vih-1
Nchioua et al. SARS-CoV-2 variants of concern hijack IFITM2 for efficient replication in human lung cells
CA3109165A1 (en) Immunogenic compositions and uses thereof
Jeeva et al. Crimean-Congo hemorrhagic fever virus nucleocapsid protein augments mRNA translation
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
BR112022001359A2 (pt) Método e composição para anticorpos anti-cd73 e variantes
Appelberg et al. A universal SARS‐CoV DNA vaccine inducing highly cross‐reactive neutralizing antibodies and T cells
BR112022021374A2 (pt) Constructo de dna, genes da proteína s de sars-cov-2, vetor, peptídeo sinal, composição imunogênica e seu método de preparação e vacina
Dong et al. A small region of porcine hemagglutinating encephalomyelitis virus spike protein interacts with the neural cell adhesion molecule
US20200163957A1 (en) Methods and compositions for enhancing immune response to vaccination
BR112023012205A2 (pt) Construto de rna, sequência de ácido nucleico, cassete de expressão, vetor recombinante, composição farmacêutica, método de preparação do construto e vacina
EP4188941A2 (en) Modified chikungunya viruses and sindbis viruses and uses thereof
Shen et al. Role of stem B, loop B, and nucleotides next to the primer binding site and the kissing-loop domain in human immunodeficiency virus type 1 replication and genomic-RNA dimerization
Sellers et al. Phylogenetic analysis of the sigma 2 protein gene of turkey reoviruses
Cochin et al. In vivo rescue of arboviruses directly from subgenomic DNA fragments
BR112022019334A2 (pt) Método para produzir um genoma viral interferente defeituoso, genomas virais interferentes defeituosos, partícula interferente defeituosa, método de tratamento de uma infecção viral, genoma interferente defeituoso, composição farmacêutica, imunogênica ou terapêutica, vacina, uso, polinucleotídeo, vetor de expressão ou plasmídeo e linhagem de células
Sarmadi et al. Vaccine approaches and treatment aspects against Crimean Congo hemorrhagic fever
Knudsen et al. Intradermal electroporation of RNA